These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 32162560)

  • 1. Approved and emerging PI3K inhibitors for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma.
    Kienle DL; Stilgenbauer S
    Expert Opin Pharmacother; 2020 Jun; 21(8):917-929. PubMed ID: 32162560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.
    Lampson BL; Brown JR
    Expert Opin Investig Drugs; 2017 Nov; 26(11):1267-1279. PubMed ID: 28945111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.
    Friedberg JW; Sharman J; Sweetenham J; Johnston PB; Vose JM; Lacasce A; Schaefer-Cutillo J; De Vos S; Sinha R; Leonard JP; Cripe LD; Gregory SA; Sterba MP; Lowe AM; Levy R; Shipp MA
    Blood; 2010 Apr; 115(13):2578-85. PubMed ID: 19965662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PI3K signaling pathway in normal B cells and indolent B-cell malignancies.
    Pongas G; Cheson BD
    Semin Oncol; 2016 Dec; 43(6):647-654. PubMed ID: 28061982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current Treatment Options in Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: a Review.
    Islam P
    Curr Treat Options Oncol; 2023 Sep; 24(9):1259-1273. PubMed ID: 37407887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring a Future for PI3K Inhibitors in Chronic Lymphocytic Leukemia.
    Patel K; Pagel JM
    Curr Hematol Malig Rep; 2019 Aug; 14(4):292-301. PubMed ID: 31203516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of idelalisib for the treatment of indolent B-cell malignancies.
    Smolewski P; Rydygier D
    Expert Opin Pharmacother; 2020 Oct; 21(15):1915-1926. PubMed ID: 32686971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.
    Yang Q; Modi P; Newcomb T; Quéva C; Gandhi V
    Clin Cancer Res; 2015 Apr; 21(7):1537-42. PubMed ID: 25670221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Idelalisib: a review of its use in chronic lymphocytic leukaemia and indolent non-Hodgkin's lymphoma.
    Keating GM
    Target Oncol; 2015 Mar; 10(1):141-51. PubMed ID: 25637459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional Testing to Characterize and Stratify PI3K Inhibitor Responses in Chronic Lymphocytic Leukemia.
    Yin Y; Athanasiadis P; Karlsen L; Urban A; Xu H; Murali I; Fernandes SM; Arribas AJ; Hilli AK; Taskén K; Bertoni F; Mato AR; Normant E; Brown JR; Tjønnfjord GE; Aittokallio T; Skånland SS
    Clin Cancer Res; 2022 Oct; 28(20):4444-4455. PubMed ID: 35998013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
    Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
    Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PI3K inhibitors in chronic lymphocytic leukemia: where do we go from here?
    Skånland SS; Brown JR
    Haematologica; 2023 Jan; 108(1):9-21. PubMed ID: 35899388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin's lymphoma.
    Rodgers TD; Reagan PM
    Expert Opin Emerg Drugs; 2018 Jun; 23(2):111-122. PubMed ID: 29781323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Idelalisib for treatment of B-cell malignancies.
    Do B; Mace M; Rexwinkle A
    Am J Health Syst Pharm; 2016 Apr; 73(8):547-55. PubMed ID: 26933132
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Barrientos JC
    Future Oncol; 2016 Sep; 12(18):2077-94. PubMed ID: 27324214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An evaluation of zanubrutinib, a BTK inhibitor, for the treatment of chronic lymphocytic leukemia.
    Geethakumari PR; Awan F
    Expert Rev Hematol; 2020 Oct; 13(10):1039-1046. PubMed ID: 32869675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current status of phosphoinotiside-3 kinase inhibitors in blood cancers.
    Shouse G; Danilova OV; Danilov AV
    Curr Opin Oncol; 2022 Sep; 34(5):540-545. PubMed ID: 35855508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.
    Burris HA; Flinn IW; Patel MR; Fenske TS; Deng C; Brander DM; Gutierrez M; Essell JH; Kuhn JG; Miskin HP; Sportelli P; Weiss MS; Vakkalanka S; Savona MR; O'Connor OA
    Lancet Oncol; 2018 Apr; 19(4):486-496. PubMed ID: 29475723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy.
    Mato AR; Ghosh N; Schuster SJ; Lamanna N; Pagel JM; Flinn IW; Barrientos JC; Rai KR; Reeves JA; Cheson BD; Barr PM; Kambhampati S; Lansigan F; Pu JJ; Skarbnik AP; Roeker L; Fonseca GA; Sitlinger A; Hamadeh IS; Dorsey C; LaRatta N; Weissbrot H; Luning Prak ET; Tsao P; Paskalis D; Sportelli P; Miskin HP; Weiss MS; Svoboda J; Brander DM
    Blood; 2021 May; 137(20):2817-2826. PubMed ID: 33259589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.